ProQR Therapeutics NV expected to post a loss of 22 cents a share - Earnings Preview

ProQR Therapeutics NV

02/08/2021 12:05

* ProQR Therapeutics NV  PRQR.OQ   PRQR.O  is expected to show a
fall in quarterly revenue when it reports results on August 4
(estimated). 
* The Leiden, Zuid-holland-based company is expected to report 
 a 97.2% decrease in revenue to €239.43 thousand from €8.67
million a year ago, according to the mean estimate from 4
analysts, based on Refinitiv data. 
​* Refinitiv's mean analyst estimate for ProQR Therapeutics NV
is for a loss of 22 cents per share. For the same quarter last
year, the company reported a loss of 8 cents per share.
* The current average analyst rating on the shares is "buy" and
the breakdown of recommendations is 8 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 
* The mean earnings estimate of analysts was unchanged in the
last three months. ​
* Wall Street's median 12-month price target for ProQR
Therapeutics NV is $21.5​, about 75.7% above​ its last closing
price of $5.23. ​​​
* Previous quarterly performance (using preferred earnings
measure in euros). ​
 QUARTER       STARMINE    REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        SMARTESTIM  IBES                 MET,    SE %
               ATE®        ESTIMATE             MISSED  
 Mar. 31 2021  -0.25       -0.25      -0.25     Met     -0.1
 Dec. 31 2020  -0.25       -0.25      -0.26     Missed  -3.6
 Sep. 30 2020  -0.30       -0.30      -0.26     Beat    13.5​
 Jun. 30 2020  -0.29       -0.33      -0.08     Beat    75.6
 Mar.          -0.34​      -0.34      -0.32     Beat    6.4​
 31​ 2020​                                              
 Dec. 31 2019  -0.35       -0.35      -0.39     Missed  -10.6​
 Sep. 30 2019  -0.33       -0.34      -0.31     Met     9.9
 Jun. 30 2019  -0.38       -0.38      -0.36     Beat    16.5
 This summary was machine generated August 2 at 11:05 GMT.  All
figures in euros unless otherwise stated